Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination

Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Amal, Al-Mulla, Mohammad R., Abubaker, Jehad, Al-Mulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459929/
https://www.ncbi.nlm.nih.gov/pubmed/34543154
http://dx.doi.org/10.1080/21645515.2021.1969855
_version_ 1784571633655087104
author Hasan, Amal
Al-Mulla, Mohammad R.
Abubaker, Jehad
Al-Mulla, Fahd
author_facet Hasan, Amal
Al-Mulla, Mohammad R.
Abubaker, Jehad
Al-Mulla, Fahd
author_sort Hasan, Amal
collection PubMed
description Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8(+)T-cell immunity.
format Online
Article
Text
id pubmed-8459929
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-84599292021-09-24 Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination Hasan, Amal Al-Mulla, Mohammad R. Abubaker, Jehad Al-Mulla, Fahd Hum Vaccin Immunother Letters Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8(+)T-cell immunity. Taylor & Francis 2021-09-20 /pmc/articles/PMC8459929/ /pubmed/34543154 http://dx.doi.org/10.1080/21645515.2021.1969855 Text en © 2021 Taylor & Francis Group, LLC
spellingShingle Letters
Hasan, Amal
Al-Mulla, Mohammad R.
Abubaker, Jehad
Al-Mulla, Fahd
Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
title Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
title_full Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
title_fullStr Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
title_full_unstemmed Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
title_short Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
title_sort early insight into antibody-dependent enhancement after sars-cov-2 mrna vaccination
topic Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459929/
https://www.ncbi.nlm.nih.gov/pubmed/34543154
http://dx.doi.org/10.1080/21645515.2021.1969855
work_keys_str_mv AT hasanamal earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination
AT almullamohammadr earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination
AT abubakerjehad earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination
AT almullafahd earlyinsightintoantibodydependentenhancementaftersarscov2mrnavaccination

Ejemplares similares